References
- AndersonIMMeta-analytical studies on new antidepressantsBr Med Bull200157161178
- StahlSMGradyMMMoretCBrileyMSNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsCNS Spectr20051073274716142213
- MitchellAJDepressed patients and treatment adherenceLancet200636795282041204316798371
- KatoMFukudaTWakenoMEffects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patientsNeuropsychobiology20065318619516874005
- SugaiTSuzukiYSawamuraKFukuiNInoueYSomeyaTThe effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetinePharmacogenomics J2006635135616534507
- YoshidaKNaitoSTakahashiHMonoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamineNeuropsychobiology200348101312886034
- MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
- SugawaraYHiguchiHYoshidaKResponse rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patientsClin Neuropharmacol2006296916518126
- TajimaOJapanese experience with dual-action antidepressantsInt Clin Psychopharmacol200217Suppl 1S374212369609
- LingjaerdeOAhlforsUGBechPDenckerSJElgenKThe UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patientsActa Psychiatr Scand19873341100
- HiguchiHYoshidaKTakahashiHMilnacipran plasma levels and antidepressant response in Japanese major depressive patientsHum Psychopharmacol20031825525912766929
- ItoKYoshidaKSatoKA variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxaminePsychiatry Res200211123523912374640
- SatoKYoshidaKTakahashiHAssociation between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorderNeuropsychobiology20024613614012422060
- YoshidaKItoKSatoKInfluence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patientsProg Neuropsychopharmacol Biol Psychiatry20022638338611817517
- YoshidaKNaitoSTakahashiHMonoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and anti-depressant response to fluvoxamine in Japanese patients with major depressive disorderProg Neuropsychopharmacol Biol Psychiatry2002261279128312502014
- JonssonEGNothenMMGustavssonJPPolymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteersPsychiatry Res199879199676821
- MarcyTRBrittonMLAntidepressant-induced sweatingAnn Pharmacother20053974875215728327
- Package insertLexapo (escitalopram oxalate)St. Louis, MOForest Pharmaceuticals82004
- TrindadeEMenonDTopferLAColomaCAdverse effects associated with selective serotonin reuptake inhibitors and tricyclic anti-depressants: a meta-analysisCMAJ1998159124512529861221
- WickershamRMDrug and comparisons 200458th edSt Louis, MOWolters Kluwer Health200310241071
- ButtMMManaging antidepressant-induced sweatingJ Clin Psychiatry1989501461472925604
- LeemanCPPathophysiology of tricyclic-induced sweatingJ Clin Psychiatry1990512582592347866
- MorishitaSAritaSDifferential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to ageHum Psychopharmacol20041940540815303244